Filing Details
- Accession Number:
- 0001209191-21-067655
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-12-02 17:10:57
- Reporting Period:
- 2021-11-30
- Accepted Time:
- 2021-12-02 17:10:57
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1706431 | Vir Biotechnology Inc. | VIR | Biological Products, (No Disgnostic Substances) (2836) | 812730369 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1821008 | Janet Napolitano | C/O Vir Biotechnology, Inc. 499 Illinois Street, Suite 500 San Francisco CA 94158 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-11-30 | 1,435 | $41.64 | 4,809 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-11-30 | 1,435 | $46.25 | 3,374 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Stock Option (Right to Buy) | Acquisiton | 2021-11-30 | 1,435 | $0.00 | 1,435 | $41.64 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
30,130 | 2030-08-28 | No | 4 | M | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2021.
- 1/3 of the shares subject to the stock option vested and became exercisable on August 28, 2021, and the remaining shares vest in 24 equal monthly installments thereafter.